Transcriptional activity of Forkhead box transcription factor class O (FOXO) proteins can result in a variety of cellular outcomes depending on cell type and activating stimulus. These transcription factors are negatively regulated by the phosphoinositol 3-kinase (PI3K)-protein kinase B (PKB) signaling pathway, which is thought to have a pivotal role in regulating survival of tumor cells in a variety of cancers. Recently, it has become clear that FOXO proteins can promote resistance to anti-cancer therapeutics, designed to inhibit PI3K-PKB activity, by inducing the expression of proteins that provide feedback at different levels of this pathway. We questioned whether such a feedback mechanism may also exist directly at the level of FOXO-induced transcription. To identify critical modulators of FOXO transcriptional output, we performed gene expression analyses after conditional activation of key components of the PI3K-PKB-FOXO signaling pathway and identified FOXP1 as a direct FOXO transcriptional target. Using chromatin immunoprecipitation followed by next-generation sequencing, we show that FOXP1 binds enhancers that are pre-occupied by FOXO3. By sequencing the transcriptomes of cells in which FOXO is specifically activated in the absence of FOXP1, we demonstrate that FOXP1 can modulate the expression of a specific subset of FOXO target genes, including inhibiting expression of the pro-apoptotic gene BIK. FOXO activation in FOXP1-knockdown cells resulted in increased cell death, demonstrating that FOXP1 prevents FOXO-induced apoptosis. We therefore propose that FOXP1 represents an important modulator of FOXO-induced transcription, promoting cellular survival.
Transcriptional activity of Forkhead box transcription factor class O (FOXO) proteins can result in a variety of cellular outcomes depending on cell type and activating stimulus. These transcription factors are negatively regulated by the phosphoinositol 3-kinase (PI3K)-protein kinase B (PKB) signaling pathway, which is thought to have a pivotal role in regulating survival of tumor cells in a variety of cancers. Recently, it has become clear that FOXO proteins can promote resistance to anti-cancer therapeutics, designed to inhibit PI3K-PKB activity, by inducing the expression of proteins that provide feedback at different levels of this pathway. We questioned whether such a feedback mechanism may also exist directly at the level of FOXO-induced transcription. To identify critical modulators of FOXO transcriptional output, we performed gene expression analyses after conditional activation of key components of the PI3K-PKB-FOXO signaling pathway and identified FOXP1 as a direct FOXO transcriptional target. Using chromatin immunoprecipitation followed by next-generation sequencing, we show that FOXP1 binds enhancers that are pre-occupied by FOXO3. By sequencing the transcriptomes of cells in which FOXO is specifically activated in the absence of FOXP1, we demonstrate that FOXP1 can modulate the expression of a specific subset of FOXO target genes, including inhibiting expression of the pro-apoptotic gene BIK. FOXO activation in FOXP1-knockdown cells resulted in increased cell death, demonstrating that FOXP1 prevents FOXO-induced apoptosis. We therefore propose that FOXP1 represents an important modulator of FOXO-induced transcription, promoting cellular survival. Forkhead box transcription factor class O (FOXO) proteins are important regulators of cell fate outcome, capable of inducing cell death as well as promoting cell survival and adaptation to environmental stress. 1 In mammals, this Forkhead subfamily consists of four members, of which the three predominant FOXO1, FOXO3 and FOXO4 display a high degree of redundancy. 2 Given their importance in modulating cellular survival, it is not surprising that FOXO activity is tightly regulated by different modes of cellular signaling. Receptor tyrosine kinase (RTK) signaling activates phosphoinositol 3-kinase (PI3K) and subsequently protein kinase B (PKB, also known as Akt), which directly phosphorylates FOXO proteins. This results in the nuclear exclusion and consequently inactivation of FOXO. 3 The PI3K-PKB-FOXO signaling module is evolutionary conserved and has been associated with regulating stress resistance and longevity in a variety of species, including the nematode Caenorhabditis elegans, 4 the fruit fly Drosophila melanogaster 5, 6 and mammals. 7, 8 Importantly, active PI3K-PKB signaling is a major prooncogenic pathway driving tumorigenesis in a diversity of tumor types. 9 Considerable effort has been directed towards the development of therapeutic agents that directly or indirectly inhibit this signal transduction pathway, such as specific PI3K and PKB, or RTK inhibitors. 10 As a consequence of this inhibition, FOXO is no longer phosphorylated by PKB, translocates to the nucleus and induces target gene expression. In addition, nuclear translocation and activation of FOXO can also be induced by various classes of chemotherapeutic compounds, 11 possibly in response to phosphorylation by p38. 12 In the nucleus, FOXO proteins induce the transcription of genes involved in a variety of biological processes, which ultimately can result in different phenotypic outcomes, depending on cell type and activating stimulus. Indeed, the chemotherapeutic agent cisplatin was shown to induce cell death through FOXO3 activation in colon carcinoma cells. 13 In contrast, leukemic cells treated with doxorubicin were reported to develop resistance through a FOXO-induced feedback mechanism by upregulation of PIK3CA, which ultimately result in increased PI3K-PKB activity.
14 Furthermore, whereas FOXO3 was shown to mediate breast cancer cell death in response to human epidermal growth factor receptor 2 inhibition, 15 PKB inhibition increases FOXO-dependent RTK signaling through upregulation of HER3. 16 These reports indicate that upon FOXO activation, cell survival mechanisms are transcriptionally induced by inducing feedback at various levels of the PI3K-PKB-FOXO pathway, including at the level of RTK signaling 16 and PI3K signaling.
14 However, to date a feedback circuit at the nuclear level has not been reported. Nevertheless, such a feedback mechanism does represent a reasonable manner for regulating the outcome of FOXO transcriptional activity, particularly as FOXO is known to have diverse nuclear interaction partners in various cellular systems. 17 For example, FOXO was reported to associate with SMAD transcription factors in regulating p21
Cip1 expression and thereby cell proliferation, 18 and with b-catenin in regulating transcriptional response to oxidative stress. 19 We speculated that if such a feedback mechanism exists, it could represent a potentially important therapeutic target given the importance of the PI3K-PKB-FOXO pathway in tumor development and in response to anticancer treatment. We therefore set out to identify FOXO transcriptional targets that in turn may directly modulate the transcriptional outcome of FOXO proteins. Here, we identify another Forkhead box protein, FOXP1, as a direct transcriptional target of FOXO. Importantly, we demonstrate that FOXP1 directly modulates FOXO-induced transcription by binding the same enhancers and modifying the expression of specific subsets of target genes resulting in cellular survival.
Results
FOXP1 is transcriptionally regulated by PI3K-PKB-FOXO signaling. To investigate the transcriptional outcome of PI3K-PKB-FOXO signaling, we systematically analyzed gene expression changes in the murine bone marrowderived cell line Ba/F3, in which clones were generated that ectopically express conditionally active variants of PI3K, PKB, FOXO3 and FOXO4. 20 To selectively activate these proteins, constitutively active versions of PI3K (myrPI3K), PKB (myrPKB), FOXO3 (FOXO3A3) or FOXO4 (FOXO4A3) were fused to the hormone-binding domain (HBD) of the estrogen receptor (ER), rendering them conditionally active after addition of tamoxifen (4-OHT). Subsequently, we performed gene expression microarray analyses to identify specific pathway transcriptional targets (Figure 1a) . 20 To identify target genes that potentially affect the transcriptional outcome of FOXO activation, we applied gene ontology (GO)-term analysis. Interestingly, we observed enrichment for genes involved in negative regulation of transcription (Figure 1b ). Among these, we found Mxi1 and Cited2, both recently described to be regulated by PI3K-PKB-FOXO activity, validating our approach. 21, 22 Using this approach, we identified the Forkhead box protein FOXP1 as a transcriptional target ( Figure 1b) . As members of the Forkhead box family share a highly conserved DNAbinding domain, they could therefore potentially regulate expression of overlapping target genes. 23 Independent Foxp1 mRNA evaluation using quantitative real-time PCR (qRT-PCR) confirmed transcriptional upregulation in murine Ba/F3 cells upon FOXO3A3-ER or FOXO4A3-ER activation (Figure 1c) . A well-characterized cellular model system for studying FOXO activation is the human colon carcinoma cell line DLD1, which has been engineered to express FOXO3A3-ER (DL23). 20, 24 Specific FOXO3A3-ER activation in this system also increased FOXP1 mRNA expression (Figure 1d ). Importantly, wild-type cells do not increase FOXP1 mRNA levels upon 4-OHT treatment, indicating specificity of the fusion protein in this response (Figures 1c  and d) . Correspondingly, activation of FOXO3(A3)-ER increased FOXP1 protein levels in various cell types, including DL23 cells (Figure 2a ) and the human osteosarcoma cell line U2OS (Figure 2b ), demonstrating that this observation is not restricted to a single cell type. Cells expressing only the ER HBD did not show increased FOXP1 protein expression after 4-OHT treatment, demonstrating the specificity of FOXO3 in FOXP1 upregulation (Figure 2b ). Indeed, activation of endogenous FOXO by inhibition of PI3K-PKB signaling or induction of a variety of environmental stress signals similarly increased FOXP1 protein levels ( Figure 2c and Supplementary Figure 1) .
The rapid increase in FOXP1 mRNA expression after specific activation of FOXO3 (B3-fold increase after 2 h of 4-OHT treatment (Figure 1d) ) suggests that FOXP1 expression is most likely directly regulated. Indeed, bioinformatics analysis of the genome-wide binding profile of FOXO3 in DLD1 cells, as determined by chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq), 25 showed specific transcription factor binding to the genomic locus where the FOXP1 gene is located after direct FOXO activation by 4-OHT treatment of DL23 cells as well as by indirect FOXO activation through PKB inhibition of DLD1 cells (Figure 3a) . Importantly, 4-OHT treatment of DL23 cells also results in RNA polymerase II (RNAPII) recruitment to two transcription start sites (TSSs) of the FOXP1 gene (Figure 3a) . RNAPII occupancy is not influenced by mRNA stability and therefore a more direct measurement for transcriptional activity. 26 To validate these analyses, we evaluated FOXO3 recruitment to the FOXP1 genomic locus in response to PKB inhibition by ChIP using a FOXO3-specific antibody followed by qPCR (ChIP-qPCR). Indeed upon PKB inhibition, we observed a significant and specific enrichment of FOXO3 binding to the genomic region that was identified by the ChIP-seq analysis (Figure 3b) . A similar result was obtained upon PI3K inhibition (Supplementary Figure 2a) and also when the assay was performed in DL23 cells upon 4-OHT treatment using a specific antibody against the ER moiety of the fusion protein (Supplementary Figure 2b) . Taken together, we demonstrate that activation of FOXO3 transcriptionally upregulates FOXP1 expression by direct binding of FOXO3 to a FOXP1 enhancer region, followed by RNAPII recruitment.
FOXP1 and FOXO3 proteins bind the same enhancers. Next, we questioned whether FOXP1 could directly affect the transcriptional outcome of FOXO3 activation by binding similar regulatory elements in the genome. To identify FOXP1 genomic-binding sites, we performed ChIP-seq in DL23 cells, which were treated with 4-OHT to ensure high FOXP1 expression levels. We made use of a validated FOXP1 antibody, which has previously been used for a similar approach. 27 In total, we identified 23 050 peaks Table 1 ).
In line with our hypothesis, FOXP1 binding was found to be enriched in promoter regions of known FOXO targets, including p27 Kip1 and CITED2 (Figure 4a ). 21, 28 Interestingly, a binding region in the promoter of the FOXP1 gene itself was among the most enriched binding sites, suggesting it can regulate its own expression ( Figure 4a ). Multiple detected regions, including binding sites near the FOXP1, CITED2 and BIK genes, have previously been identified as FOXP1-binding sites in different cellular systems using ChIP-seq technology, 27, 29 validating the specificity of our approach. Importantly, we could independently validate FOXP1 recruitment to these loci in DL23 cells upon 4-OHT treatment by ChIP-qPCR ( Figure 4b ). De-novo motif search verified the presence of a Forkhead-binding motif in a large proportion of the peaks (Figure 4c ). The most enriched Forkhead-binding motif (TGTTTAC), which is present in B30% of the peaks, has recently been shown to be the most optimal binding site for FOXP1 in embryonic stem cells. 27 Notably, this motif has also been described to be to most optimal binding site for FOXO3 in different cell systems, including DL23. 25, 30 In addition, we found enrichment for AP-1-and GATA-binding motifs in the FOXP1 peaks, which were also found to be enriched in FOXO3-binding regions, 31 further supporting our hypothesis that these two transcription Figure 4) . 25 Of note, the duration of PI3K-PKB inhibition used to determine FOXO3 binding (30 min, Figure 4d ) was much shorter than the duration of 4-OHT treatment for establishing FOXP1 genomic-binding sites (16 h, Figure 4d ), suggesting FOXO3-induced expression of FOXP1 may result in displacement of FOXO3 from DNAbinding sites. To rule out direct interaction of FOXO3 and FOXP1, we performed co-immunopreciptation experiments using overexpressed tagged versions of the two transcription factors, but did not observe any interaction (Supplementary Figure 5) . From these data, we conclude that FOXP1 and FOXO3 share a large proportion of genomic-binding sites and that their binding most probably occurs sequentially.
FOXP1 regulates expression of a specific subset of FOXO target genes. To initially investigate the effect of FOXP1 on FOXO3-mediated expression, we performed a FOXO reporter assay. 30 Transfection of FOXO3 with a luciferase reporter construct containing multiple copies of the core FOXO-binding site (TTGTTTAC) resulted in a strong activation of luciferase activity (Figure 4e Figure 5a ). Subsequently, we performed gene expression analysis by next-generation sequencing of transcriptomes (RNA-seq). First, we defined genes regulated by FOXO with expression changes of at least twofold in cells transfected with control siRNA (siSCR) and treated with 4-OHT for 8 h compared with untreated siSCR-transfected cells. Using these criteria, we identified 3014 genes that were differentially expressed after FOXO3(A3)-ER activation, including previously identified FOXO target genes (Figure 5b and Supplementary Table 2 ). Next, we determined the number of genes that were at least twofold differentially expressed in FOXP1-KD cells treated with 4-OHT compared with siSCR-transfected cells. In total, 1296 differentially expressed genes were identified of which 273 have a FOXP1 ChIP-seq peak at least 10 kb from the TSS (Figure 5b ). In line with the 6xDBE reporter assay (Figure 4e ), many genes that have a FOXP1 ChIP-seq peak within 10 kb of the TSS were found to be upregulated in FOXP1-depleted cells upon 4-OHT treatment compared with control cells, such as LGR4 and ADM (Figure 5b ). This suggests that FOXP1 inhibits FOXO-induced expression of these genes. However, we also observed many FOXOregulated genes that were unaffected by FOXP1 depletion, but have a FOXP1 ChIP-seq peak within 10 kb of the TSS, such as p27 Kip1 , CITED2 and GADD45B (Figures 4a and 5b) . Furthermore, the expression of another subset of genes that have a FOXP1 ChIP-seq peak within 10 kb of the TSS was found to be negatively affected by FOXP1 KD, including (Figure 5b ). These data suggest that FOXP1 can modify FOXO-induced transcription toward a specific cellular outcome by specifically repressing the expression of a subset of genes while inducing the expression of others. To predict the effect of FOXP1 activity on cellular fate, we performed GO-term analyses evaluating the genes that were differentially expressed in FOXP1-KD cells upon FOXO activation compared with control cells. Interestingly, genes that were upregulated in FOXP1-depleted cells compared with control cells showed enrichment for apoptosis, including genes such as BIK and FAS (Figures 5c and d) . In contrast, the expression of FOXO target genes that were negatively affected by FOXP1 depletion showed enrichment for cell migratory processes, including genes such as ETS1 and EFNB2 (Figure 5c ). This suggests that on one hand FOXP1 can induce cell survival by inhibiting FOXO-induced expression of pro-apoptotic genes, while on the other hand it may promote cell migration (Figure 5c ). Independent evaluation of BIK mRNA and protein levels verified that this gene is indeed negatively regulated by FOXP1 activity upon FOXO activation (Figures 5e and f) . Importantly, the presence of FOXP1 ChIP-seq peak within the BIK gene locus suggests that FOXP1-mediated repression of this gene occurs in a direct fashion (Supplementary Figure 6) .
FOXP1 prevents FOXO3-induced cell death. Increased expression of BIK is known to result in apoptosis through mitochondrial-induced cell death. 32 Depending on cell type, FOXO activity can either induce cell death or cell cycle arrest. In DLD1 cells, FOXO-induced transcription results in cell cycle arrest in a p27
Kip1 -dependent manner. 31 Here, we show that FOXP1 negatively affect FOXO-dependent transcription of genes involved in inducing cell death, including BIK. Therefore, we questioned whether FOXP1 can indeed promote cellular survival in response to FOXO activation in this system. To test this, we performed FOXP1 KD in DL23 cells, specifically activated FOXO3 by 4-OHT and measured the protein levels of cleaved caspase-3 as a measure of apoptosis. Increased expression of cleaved caspase-3 was only observed upon activation of FOXO3A3-ER in FOXP1-KD cells (Figure 6a ), suggesting that FOXP1 expression prevents FOXO3-induced cell death. Indeed, whereas FOXO3 activation in DL23 cells induces an arrest in cell proliferation, we observed significant decreased survival in response to 4-OHT treatment of FOXP1-depleted cells (Figures 6b and d) . Importantly, FOXP1 KD in untreated DL23 cells does not result in decreased survival compared with control cells (Figures 6b and c) . Therefore, FOXP1 specifically prevents FOXO3-induced cell death, and not just an increase in overall survival. Taken together, we show that FOXP1 is an important molecular determinant of FOXOinduced transcriptional outcome by protecting against FOXO3-induced cell death. 
Discussion
Activation of FOXO-induced transcription can result in a variety of cellular outcomes, including cell cycle arrest or cell death, which is cell and tissue type dependent. 33 Indeed, whereas FOXO activity induces cell cycle arrest in DLD1 cells, A14 cells, mouse embryonic fibroblasts and 786-0 cells, 31, 34 it induces cell death in bone marrow-derived Ba/F3 cells. 35 However, the molecular mechanisms underlying this cell type specificity remains poorly understood. One explanation for cell type-specific outcome of FOXO activation is the availability of functionally interacting proteins, such as other transcription factors or transcriptional cofactors. Here, we demonstrate a novel feedback mechanism in which increased FOXP1 expression prevents FOXO-induced cell death by directly modulating the expression of a specific subset of FOXO target genes, including BIK (Figure 5d ). Although FOXO proteins also induce the expression of FOXP1 in Ba/F3 cells, these cells still induce apoptosis in response to FOXO activation, in contrast to DLD1 cells where FOXP1 induction prevents FOXO-induced cell death. One explanation for this difference could be that the increase in FOXP1 expression by FOXO3 in Ba/F3 cells is not as prominent as in DLD1 cells (3 to 4-fold increase in Ba/F3 versus 15-fold in DLD1, Figures 1c  and d) . Furthermore, FOXO3-induced FOXP1 mRNA expression appears to be transient in Ba/F3 cells (Figure 1c) , whereas this remains high in DLD1 cells (Figure 1d ). Another explanation relates to the observations that in Ba/F3 cells FOXO3 induces apoptosis through upregulation of the pro-apoptotic protein BIM. 35 We did not observe upregulation of BIM mRNA in FOXP1-KD DL23 cells upon FOXO3 activation, suggesting that BIM is not a FOXP1 target. Indeed, we do not observe a binding peak of FOXP1 in the genomic locus of BCL2L11, the gene that encodes BIM. This suggests that apoptosis is induced through a distinct pathway in Ba/F3 cells that is apparently unaffected by FOXP1 activity.
In naïve T cells, it has been shown that FOXP1 antagonizes FOXO1-induced expression of IL7RA by directly competing for enhancer-binding site. 36 Our observation that FOXP1 and FOXO3 share a significant number of DNA-binding sites at a genome-wide scale, suggests that antagonizing FOXOinduced transcription may be a general feature of FOXP1. Indeed, we demonstrate that FOXP1 modulates FOXO3-induced gene expression, both in a reporter assay as well as at a global level. However, not all genes that can be bound at their enhancers by both transcription factors are transcriptionally downregulated by FOXP1, arguing against a general antagonistic role in relation to FOXO-induced gene expression. Indeed, the expression of many genes, including prototypic FOXO target genes such as p27 Kip1 , CITED2 and GADD45B, is not affected by binding of FOXP1 to their enhancers. Of note, it is not likely that FOXO3 and FOXP1 interact at these genomic sites, as we could not detect any interaction between the two transcription factors by co-immunoprecipitation. This suggests that although the expression levels of the target genes are not affected by FOXP1, FOXO3 is likely to be replaced from the enhancers by FOXP1. In addition, the FOXO-induced expression of a subset of genes seems to be enhanced in the presence FOXP1 as depletion of it results in lower FOXO-induced expression levels. These FOXP1-dependent gene expression differences may suggest that the presence or absence of yet other cofactors or transcription factors at specified enhancers can be important to determine if a FOXP1 target is up-or downregulated in response to FOXO activation. In support of this hypothesis, we do find significant enrichment of AP-1-and GATA-binding motifs in FOXP1-bound genomic regions as determined by ChIP-seq, suggesting that these transcription factors might physically or functionally interact. Recently, it was shown that FOXP3 almost exclusively binds enhancer sites, which were pre-accessed by either cofactors or structurally related transcription factors, such as FOXO1. 37 It might well be that FOXP1, similar to FOXP3, exploits preexisting enhancers in a similar manner by displacing FOXO3 from these sites. This would explain the high degree of DNAbinding site overlap between the two transcription factors. The ultimate result of FOXP1 antagonizing FOXO3 binding of enhancer elements is not overall downregulation of all target genes, but rather a specific transcriptional outcome that protects against FOXO-induced cell death and possibly promotes cell migration.
In agreement with a pro-survival and possibly a promigratory function in our system are the reports that indicate an oncogenic role for FOXP1 in cancer. For example, FOXP1 is highly expressed in a subgroup of diffuse large B-cell lymphoma as well as in a mucosal-associated lymphoid tissue type of marginal zone B-cell lymphoma, which in both cancers is strongly associated with decreased patient survival. 38, 39 In contrast, loss of FOXP1 expression has been reported in a variety of solid tumors, including colon and breast tumors, 40 indicating a tumor-suppressive role in this context. Indeed, high FOXP1 expression levels in breast cancer were found to be associated with increased patient survival. 41 This latter observation seems to conflict with our finding that FOXP1 protects against cell death while promoting cell migration. However, we observe this FOXP1-induced cell survival phenotype exclusively after activating FOXO3, while FOXP1 KD alone does not affect growth rate. Furthermore, in line with their role in regulating apoptosis, cell cycle arrest and DNA damage response, FOXO proteins are considered to be tumor suppressors. Simultaneous deletion of FOXO1, FOXO3 and FOXO4 results in spontaneous tumor formation in the hematopoietic system (predominantly lymphoblastic thymic lymphoma) of mice. 42 The antagonistic action of FOXP1 against FOXO-induced cell death therefore argues for an oncogenic role of FOXP1 in tumorigenesis. However, deletion of FOXO proteins also results in depletion of multipotent stem cells, including hematopoietic stem cells 43 as well as neural stem cells, 44, 45 due to a decrease in self-renewal and an increase in differentiation in different tissues. This latter finding appears at first inconsistent with the tumor-suppressor activity of FOXO proteins as uncontrolled self-renewal is a prerequisite for tumor formation and differentiation is antitumorigenic. Furthermore, a recent study demonstrates a pro-oncogenic role for FOXO transcription factors in acute myeloid leukemia. 46 It could be that for FOXP1 a similar cellular context difference might exist; however, this still has to be determined.
Given the relevance of FOXO in inducing cancer cell death in response to anti-cancer treatment, 11 FOXP1 might represent a therapy resistance marker. Indeed, we show that FOXP1 inhibits FOXO3-induced cell death, while promoting the expression of genes that are involved in cell migration and angiogenesis. In line with this, FOXP1 expression is increased in colorectal cancer cells in response to treatment with the chemotherapeutic doxorubicin as well as after specific inhibition of PI3K-PKB signaling. We propose that similar to FOXO-induced HER3 and PIK3CA expression in response to cancer therapy aimed at inhibiting PI3K-PKB signaling, 14, 16, 47 FOXP1 possibly represents another mode of developing escape from treatment by protecting the cells against FOXO-induced cell death.
Taken together, we have shown that FOXP1 is a direct transcriptional target of FOXO proteins. Importantly, we demonstrate that FOXP1 binds the same genomic enhancer elements as FOXO, potentially in a sequential matter, thereby directing the transcriptional outcome of FOXO proteins toward cellular survival. Therefore, FOXP1 represents an important determinant of FOXO-induced cellular outcome and possibly explains the difference in the response of different cell types to FOXO activation.
Materials and Methods
Cell culture. Ba/F3 cells expressing FOXO3(A3)-ER have been described previously 20 and were cultured in RPMI containing GlutaMAX (Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% HyClone serum (Gibco Life Technologies, Carlsbad, CA, USA) and recombinant mouse IL-3 produced in COS cells. 48 DLD1 cells expressing FOXO3(A3)-ER (DL23) have been described previously. 24 For the generation of polyclonal U2OS cells expressing FOXO3(A3)-ER, linearized pcDNA3-HA-FOXO3(A3)-ER or pcDNA3-ER 28 were electroporated into the cells. The cells were subsequently selected and maintained in the presence of 1 mg ml À 1 G418 (Gibco). DLD1 and U2OS cells were cultured in DMEM containing GlutaMAX supplemented with 10% fetal bovine serum. KD of FOXP1 in DL23 was achieved by transfection using Lipofectamine RNAiMAX reagents (Invitrogen) with 10 nM human FOXP1 siRNA (Thermo Scientific, ON-TARGET plus SMARTpool, L-004256-01, Waltham, MA, USA) at least 24 h before 4-OHT treatment.
Quantitative real-time PCR. RNA was isolated using a RNeasy kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's protocol. cDNA was generated by reverse transcribing 1 mg of total RNA with SuperScript III reverse transcriptase (Invitrogen Life Technologies). Quantitative PCR was subsequently performed using an Biorad Icycler (Bio-Rad, Hercules, CA, USA) with primer pairs for the indicated gene and normalized using primer pairs for GAPDH. Primer sequences can be found in Supplementary Table 3 .
Western blotting. Western blot analysis was performed as described. 20 In brief, cells were lysed in Laemmli buffer and protein concentration was determined using a Lowry protein assay. Equal amounts of protein were separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was incubated with the appropriate amount of antibody according to the manufacturer's indicated conditions. The antibodies against FOXP1 (2005) and cleaved Caspase-3 (9661) were from Cell Signaling Technology (Danvers, CA, USA), ER (MC-20, sc-542) and BIK (N-19, sc-1710) from Santa Cruz Biotechnology (Santa Cruz, CA, USA), p27 Kip1 (610241) from BD Biosciences (San Jose, CA, USA), and tubulin (T5168), HA-tag (H3663) and FLAG-tag (F7425) from Sigma Aldrich (Saint Louis, MI, USA). Immunocomplexes were detected using ECL (Amersham Pharmacia Inc. (GE Healthcare), Piscataway, NJ, USA).
